Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 78
Filter
Add more filters

Country/Region as subject
Publication year range
1.
J Neural Transm (Vienna) ; 130(2): 77-85, 2023 02.
Article in English | MEDLINE | ID: mdl-36550202

ABSTRACT

Axial postural abnormalities and pain are two main determinants of poor quality of life in patients with Parkinson's disease (PD). Indeed, a detailed characterization of pain and other non-motor symptoms in patients with PAs has not been provided yet. The aim of this study is to assess the phenomenology of pain and other non-motor symptoms in PD patients with Pisa syndrome and camptocormia compared to PD patients without axial postural abnormality. Forty-five PD participants were equally distributed in three groups: patients with Pisa syndrome (PS), patients with Camptocormia (CC), and patients without postural abnormalities (PD). Pain characteristics were assessed by Kings Parkinson's Pain Scale (KPPS), brief pain inventory (BPI), and numeric pain rating scale (NRS). All participants completed clinical assessments by non-motor symptom scale (NMSS), and movement disorder society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II-III. Patients with and without axial postural abnormalities showed one or more types of pain, being fluctuation, nocturnal, chronic, and musculoskeletal the most frequently reported in Pisa Syndrome and camptocormia. PD group compared with PS and CC groups showed differences in the KPPS, NMSS, BPI pain severity and interference, and NRS total scores. No significant differences were found between PS group compared with CC group with exception of the NMSS total scores. PD patients with Pisa syndrome or camptocormia have a higher burden of musculoskeletal, chronic and fluctuation pain than PD patients without axial postural abnormalities, suggesting different etiologies of pain and possible different treatments.


Subject(s)
Parkinson Disease , Spinal Curvatures , Humans , Parkinson Disease/complications , Parkinson Disease/diagnosis , Quality of Life , Spinal Curvatures/complications , Pain/complications , Syndrome
2.
BMC Neurol ; 22(1): 432, 2022 Nov 15.
Article in English | MEDLINE | ID: mdl-36380304

ABSTRACT

BACKGROUND: Pisa syndrome (PS), characterized by lateral trunk flexion, is quite common in patients with Parkinson's disease (PD). Patients with PS are older and have a significantly longer disease duration, more severe motor phenotype, ongoing combined treatment with levodopa and dopamine agonists, and higher levodopa equivalent daily dose. We describe here, to the best of our knowledge, the first case of a woman with PD who developed acute-onset PS caused by chronic subdural hematoma (CSDH). CASE PRESENTATION: A 70-year-old woman developed acute-onset lateral flexion of her trunk to the left side while standing, and she was admitted to our hospital. One month before, she had a mild head trauma with loss of consciousness. At 65 years of age, she noticed difficulty with walking and clumsiness with her hands. She was diagnosed as having PD (Hoehn and Yahr stage 2) and levodopa was initiated. Her symptoms were markedly improved. At 67 years of age, she developed orthostatic hypotension and was treated sequentially with fluids, compression stockings, and midodrine. Urgently performed brain computed tomography (CT) showed a CSDH in the right hemisphere resulting in a marked compression of the hemisphere. After surgical evacuation, her PS disappeared. She has fully recovered to her preoperative level of function. CONCLUSION: The present case provides a valuable insight, that is, the mesial frontal lobe and its connections from the posterior parietal cortex play crucial roles in maintaining the body schema and in the pathophysiology of PS. This case suggests that CSDH should be considered when clinicians examine acute-onset PS, even in patients with neurodegenerative disorders such as PD. Appropriate patient triage and timely neurosurgical intervention should be considered.


Subject(s)
Hematoma, Subdural, Chronic , Parkinson Disease , Female , Humans , Parkinson Disease/complications , Parkinson Disease/drug therapy , Parkinson Disease/diagnosis , Hematoma, Subdural, Chronic/complications , Hematoma, Subdural, Chronic/diagnostic imaging , Hematoma, Subdural, Chronic/surgery , Levodopa/adverse effects , Syndrome , Dopamine Agonists
3.
Int J Neurosci ; 131(6): 521-526, 2021 Jun.
Article in English | MEDLINE | ID: mdl-32942935

ABSTRACT

INTRODUCTION: Lateral trunk flexion (LTF) is a common postural deformity in Parkinson's disease (PD). Postural control is known to depend on visual, vestibular, and somatosensory information. OBJECTIVES: This study aimed to investigate the relationship between vestibular dysfunction and postural abnormalities in PD patients with LTF. METHODS: We enrolled a total of 19 PD patients with LTF (PD-LTF+) and 19 age- and sex-matched PD patients without LTF (PD-LTF-). All patients underwent vestibular tests, including spontaneous nystagmus, gaze-evoked nystagmus, ocular movements, optokinetic eye test, fast positioning maneuvers, and the bithermal caloric test. RESULTS: Most of the PD-LTF + patients had abnormal vestibular function (11/19), while there were fewer vestibular function injuries in the control group (3/19). In PD-LTF + group, there were 5 patients (5/11, 45.5%) of peripheral vestibular dysfunction, 2 patients (2/11, 18.2%) of central vestibular damage, and 4 patients (4/11, 36.4%) of mixed injuries. The peripheral vestibular deficiencies could be either bilateral (4/9, 44.4%) or unilateral (5/9, 55.6%). The unilateral vestibular dysfunction was ipsilateral to the leaning side in 2 patients and contralateral to the leaning side in the other 3 patients. CONCLUSION: Vestibular dysfunction may be an independent risk factor for LTF in PD patients.


Subject(s)
Parkinson Disease/physiopathology , Postural Balance/physiology , Torso/physiopathology , Vestibular Diseases/physiopathology , Aged , Female , Humans , Male , Middle Aged , Risk Factors , Vestibular Diseases/diagnosis , Vestibular Function Tests
4.
Ideggyogy Sz ; 74(9-10): 356-360, 2021 Sep 30.
Article in English | MEDLINE | ID: mdl-34657399

ABSTRACT

Pisa syndrome is a movement problem defined by tonic, sustained lateral flexion with a slight posterior rotation of the trunk. It seems to be a side effect of antipsychotic medicine in most cases. The clinical duration of Pisa syndrome can be acute, chronic, or recurrent. As far as we know, no reports are available in the literature on the chronic form of Pisa syndrome caused by low-dose amisulpride. A case of refractory tardive dystonia form of Pisa syndrome during treatment with stable low-dose amisulpride is presented in this report. Long-term, low-dosage amisulpride therapy may induce tardive dystonia even in patients with no other risk factors for dystonia.


Subject(s)
Antipsychotic Agents , Dystonia , Amisulpride , Antipsychotic Agents/adverse effects , Dystonia/chemically induced , Humans , Syndrome
5.
BMC Neurol ; 20(1): 183, 2020 May 13.
Article in English | MEDLINE | ID: mdl-32404068

ABSTRACT

BACKGROUND: Pisa syndrome (PS) is characterized by an abnormally sustained posture, with flexion of the body and head to one side and slight rotation of the trunk. Although PS most commonly arises as an adverse effect of antipsychotic drugs, choline-esterase inhibitors (ChEIs) are also sometimes known to induce PS. Despite the fact that the precise mechanism remains unclear, cholinergic-dopaminergic imbalance has been considered as a possible pathophysiologic mechanism underlying the genesis of PS. CASE PRESENTATION: We hereby report the case of a 60-year-old woman with Alzheimer's disease who presented with the signs of PS after her treatment was switched to galantamine, a type of ChEI, even though she had received donepezil, another type of ChEI, for 5 years without any complications. To the best of our knowledge, this is the first report of PS associated with treatment switch from one to another type of ChEI. Galantamine, but not other ChEIs, can enhance striatal dopamine release through allosteric modulation of the nicotinic acetylcholine receptor, and has weaker muscarinic effects than donepezil. Therefore, we propose two novel hypotheses to explain the development of PS, as follows; galantamine, which enhances dopamine release, can induce imbalance of dopamine levels in the striatum of patients with dementia, resulting in PS, and the weaker muscarinic effects of the drug could be one of the factors predisposing to the development of PS. CONCLUSION: The present case suggests that treatment with galantamine is associated with a higher risk of development of PS than that with other ChEIs, such as donepezil, despite the pharmacological profile of galantamine as a dopamine modulator. Also, this report provides novel insight into another plausible mechanism underlying the development of PS, besides cholinergic-dopaminergic imbalance, namely, dopamine imbalance in the striatum with muscarinic-nicotinic imbalance.


Subject(s)
Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/adverse effects , Galantamine/adverse effects , Tardive Dyskinesia/chemically induced , Donepezil/therapeutic use , Female , Humans , Middle Aged
6.
J Stroke Cerebrovasc Dis ; 29(8): 104882, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32417237

ABSTRACT

Pisa syndrome is usually seen in patients with Alzheimer's disease treated with a cholinesterase inhibitor, dementia with Lewy bodies, Parkinson's disease, or atypical parkinsonism including multiple system atrophy. An 86-year-old woman presented with an acute onset of lateral flexion of her trunk to the left side, i.e., Pisa syndrome. She also showed left hemiparesis predominantly in her lower extremity. Her diffusion-weighted magnetic resonance images showed acute infarction in the right premotor area and supplementary motor area. Clopidogrel (75 mg daily) was prescribed. After two weeks from the onset of symptoms, her Pisa syndrome improved. The pathophysiology of Pisa syndrome has not yet been fully understood, but different mechanisms have been assumed. In this patient, it is possible that the infarction in her unilateral frontal lobe impaired the information processing from the temporoparietal cortex to the frontal lobe, including the premotor area and supplementary motor area for anticipatory postural control.


Subject(s)
Cerebral Infarction/complications , Dystonia/etiology , Frontal Lobe/blood supply , Frontal Lobe/physiopathology , Posture , Aged, 80 and over , Cerebral Infarction/diagnostic imaging , Cerebral Infarction/drug therapy , Cerebral Infarction/physiopathology , Clopidogrel/therapeutic use , Dystonia/diagnosis , Dystonia/physiopathology , Female , Humans , Platelet Aggregation Inhibitors/therapeutic use , Recovery of Function , Syndrome , Treatment Outcome
7.
Neurol Neurochir Pol ; 53(4): 291-295, 2019.
Article in English | MEDLINE | ID: mdl-31441493

ABSTRACT

AIM OF THE STUDY: Postural deformities are common in Parkinson's disease (PD) patients. Several treatment options have been reported, but responses to these treatments appear unpredictable. Istradefylline is a novel drug for PD. Cases of PD patients whose postural deformities were improved after withdrawal of dopamine agonists and initiation of istradefylline are presented. MATERIALS AND METHODS: Four consecutive patients with postural deformities including antecollis, Pisa syndrome, and camptocormia were recruited and treated with istradefylline in combination with withdrawal of dopamine agonists, which are possible causes of postural deformities. RESULTS: The dopamine agonists were discontinued an average of 26 months after the development of the postural deformities, and istradefylline was initiated an average of 1.3 months after dopamine agonist withdrawal. Three patients with preserved paraspinal muscle volume showed good responses to the treatment regimen at least two months after dopamine agonist withdrawal. CONCLUSIONS AND CLINICAL IMPLICATIONS: Postural deformities caused by dopamine agonists generally improve less than two weeks after dopamine agonist withdrawal. Given the response time in the present study, the response was unlikely to be caused solely by dopamine agonist withdrawal. Istradefylline can be a potential therapeutic option; however, appropriate selection of patients for treatment with istradefylline is warranted.


Subject(s)
Muscular Atrophy, Spinal , Parkinson Disease , Purines/therapeutic use , Spinal Curvatures , Humans , Parkinson Disease/drug therapy
8.
Laeknabladid ; 105(5): 231-235, 2019.
Article in Is | MEDLINE | ID: mdl-31048557

ABSTRACT

This case report describes a 66-year old woman with Parkinson´s disease and a subacute onset lateral postural deformity. She experienced severe back pain and reduced walking ability. She was diagnosed with Pisa syndrome and sagittal and coronal imbalance was observed on radiographs. Posterior reconstructive surgery was performed from sacrum to Th10. Post operatively, sagittal and coronal imbalance was improved and maintained at the two year follow-up. The patient remained pain free and improvements in walking ability were sustained. The caveats of spine surgery in Parkinson´s patients are discussed and the importance of goal oriented surgery in terms of improvements in sagittal and coronal balance.


Subject(s)
Back Pain/etiology , Parkinson Disease/complications , Postural Balance , Spine/surgery , Aged , Back Pain/diagnosis , Back Pain/physiopathology , Back Pain/surgery , Female , Humans , Mobility Limitation , Parkinson Disease/diagnosis , Parkinson Disease/physiopathology , Recovery of Function , Severity of Illness Index , Spine/diagnostic imaging , Spine/physiopathology , Treatment Outcome
10.
Acta Neurol Scand ; 137(5): 481-487, 2018 May.
Article in English | MEDLINE | ID: mdl-29285760

ABSTRACT

OBJECTIVES: We sought to assess the efficacy of subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson's disease (PD)-associated trunk posture abnormalities retrospectively analyzing data from 101 patients reporting mild-to-severe trunk posture abnormalities of a cohort of 216 PD patients treated with STN-DBS at our center. METHODS: Abnormal trunk posture was rated on a scale of 0 (normal) to 4 (marked flexion with an extreme abnormality of posture) as per the grading score reported in the Unified Parkinson's Disease Rating Scale. The independent effect of STN-DBS on trunk posture was assessed comparing Medication-Off (presurgery) vs Stimulation-On/Medication-Off (post-surgery). The combined effect of STN-DBS plus levodopa was evaluated comparing Medication-On (presurgery) vs Stimulation-On/Medication-On (post-surgery). Analyses were conducted considering both the entire cohort of patients and the subgroup with camptocormia (CMC) and Pisa syndrome (PS). RESULTS: The independent effect of STN-DBS resulted in a 41.4% improvement in abnormal trunk posture severity (P < .001), with 78.2% of patients (n = 79) reporting an improvement of at least 1 point. The combined effect of STN-DBS and levodopa resulted in a 30.9% improvement (P = .061), with 54.5% of patients (n = 55) reporting an improvement of at least 1 point. The subanalysis of patients with CMC (n = 23) and PS (n = 5) showed a 42.7% improvement in abnormal posture severity when considering the independent effect of STN-DBS (P < .001) and 30.5% when considering the combined effect of STN-DBS and levodopa (P < .001). CONCLUSIONS: STN-DBS may have the potential for improving posture in patients with advanced PD.


Subject(s)
Deep Brain Stimulation/methods , Parkinson Disease/therapy , Posture , Adult , Aged , Cohort Studies , Female , Humans , Male , Middle Aged , Muscular Atrophy, Spinal/etiology , Muscular Atrophy, Spinal/therapy , Parkinson Disease/complications , Subthalamic Nucleus/physiology
11.
BMC Neurol ; 17(1): 148, 2017 Aug 03.
Article in English | MEDLINE | ID: mdl-28774283

ABSTRACT

BACKGROUND: Spinal cord stimulation (SCS) has recently been reported to be effective for truncal postural abnormalities such as camptocormia and Pisa syndrome in Parkinson's disease. In this case report, we describe a case of a woman with Parkinson's disease in whom SCS was effective for painful camptocormia with Pisa syndrome. CASE PRESENTATION: A 65-year-old woman was admitted to our hospital because of painful camptocormia. She had noticed resting tremor in the left upper limb and aprosody at 48 years of age. She was diagnosed as having Parkinson's disease (Hoehn & Yahr stage 1) at 53 years of age. Cabergoline was started during that same year, with subsequent addition of selegiline hydrochloride; the symptoms of parkinsonism disappeared. Wearing-off occurred when she was 57 years old, 3 years after starting carbidopa/levodopa, and truncal postural abnormalities-painful camptocormia with Pisa syndrome to the right-appeared at 58 years of age. These symptoms worsened despite adjustment of her oral medications, and deep brain stimulation (DBS) was performed when she was 60 years old. The truncal postural abnormalities improved after DBS, and she could travel abroad at 61 years of age. However, from 62 years of age, painful camptocormia with Pisa syndrome to the right reappeared. The pain was unsuccessfully treated with oral analgesics, radiofrequency coagulation of the dorsal and medial branches of the lumbar spinal nerve, and lumbar epidural block. Finally, SCS was performed for the pain relief. The pain disappeared immediately after SCS and her posture then gradually improved. Unified Parkinson's Disease Rating Scale score improved from 48 to 34 points and Timed Up and Go Test improved from 15 s to 7 s after SCS. CONCLUSIONS: This case suggests that SCS may be effective for improving painful truncal postural abnormalities and motor complications of Parkinson's disease. Pain relief or a direct effect on the central nervous system by SCS was considered to explain the alleviation of these symptoms.


Subject(s)
Muscular Atrophy, Spinal/therapy , Parkinson Disease/therapy , Spinal Cord Stimulation/methods , Spinal Curvatures/therapy , Aged , Female , Humans , Muscular Atrophy, Spinal/etiology , Parkinson Disease/complications , Spinal Curvatures/etiology
12.
Age Ageing ; 46(3): 529-530, 2017 05 01.
Article in English | MEDLINE | ID: mdl-28104598

ABSTRACT

We report a case of Pisa syndrome (PS) due to the acetylcholinesterase inhibitor donepezil which may have been precipitated by pharmacokinetic interactions with commonly used medications. PS is defined as a reversible lateral bending of the trunk with a tendency to lean to one side. This is a rare but very distressing complication with this commonly used medication which was not initially recognised, leading to increasing disability for the patient and significant carer stress. Cessation of donepezil and modulation of potential interacting medications resulted in complete resolution.


Subject(s)
Cholinesterase Inhibitors/adverse effects , Dystonic Disorders/chemically induced , Indans/adverse effects , Piperidines/adverse effects , Postural Balance/drug effects , Aged, 80 and over , Cholinesterase Inhibitors/pharmacokinetics , Donepezil , Drug Interactions , Dystonic Disorders/diagnosis , Dystonic Disorders/physiopathology , Humans , Indans/pharmacokinetics , Male , Omeprazole/adverse effects , Omeprazole/pharmacokinetics , Piperidines/pharmacokinetics , Polypharmacy , Proton Pump Inhibitors/adverse effects , Proton Pump Inhibitors/pharmacokinetics , Risk Factors
13.
Eur Spine J ; 26(7): 1862-1870, 2017 07.
Article in English | MEDLINE | ID: mdl-28281005

ABSTRACT

BACKGROUND: Postural deformities in the coronal plane were frequent and disabling complications of PD, which reduces the quality of life of patients. This study aimed to garner greater attention to the Parkinson disease (PD)-related postural trunk deviations in the coronal plane by exploring a method for diagnosis because of the lack of any uniform diagnostic criteria and epidemiological studies. It also aimed to provide correlation data in the Chinese PD patients. METHODS: In this cross-sectional study, 503 consecutive outpatients with PD were enrolled who underwent standardized clinical evaluation. The study recruited 83 PD patients diagnosed with Pisa syndrome (PS). Scoliosis and coronal imbalance were diagnosed accurately by radiographic data. The PD patients were compared based on the Cobb angle and coronal balance for several demographic and clinical variables. RESULTS: PD patients with PS had a prevalence of 16.5%. The prevalence of coronal imbalance and scoliosis was 10.34 and 7.75%, respectively. PD patients with PS were older and had a more severe disease, significantly longer disease duration and treatment duration, and reduced quality of life. The most important finding was that the different morphology of the spinal level had an effect on the severity of coronal balance or Cobb angle. CONCLUSIONS: The present study indicated that the postural deformities in the coronal plane were related to the morphology of the spinal level, especially the position of the Cobb angle. To benefit the PD patients with PS, the full-length standing spine radiographs should be performed as early as possible.


Subject(s)
Parkinson Disease/complications , Scoliosis/diagnosis , Scoliosis/etiology , Aged , China , Cross-Sectional Studies , Female , Humans , Linear Models , Male , Middle Aged , Prevalence , Prospective Studies , Radiography , Risk Factors , Scoliosis/epidemiology
14.
J Dual Diagn ; 13(2): 157-165, 2017.
Article in English | MEDLINE | ID: mdl-27935442

ABSTRACT

BACKGROUND AND AIMS: Dual diagnosis commonly occurs among patients with an opioid use disorder. Treatment is ideally performed in an integrated fashion. We present a case that illustrates the complex and challenging psychiatric and medical therapy of such patients in the light of the literature. CASE DESCRIPTION: We report on a 56-year-old patient with schizophrenia and opioid dependence who experienced both risperidone-induced Pisa syndrome and, 3 years later, acute psychosis after switching the opioid substitution medication from methadone to slow-release oral morphine due to QT prolongation. CONCLUSIONS: With the current availability of a diversity of substitution opioids in Switzerland (methadone, buprenorphine, diacetylmorphine, sustained-release oral morphine), studies on differential effectiveness of these agents in opioid-dependent subpopulations with selective comorbidity profiles are desirable. The same is true for further investigation of the involvement of the opioid receptor system in schizophrenia. In clinical practice, any alteration of opioid medication in patients with dual diagnosis and a history of schizophrenia should be accompanied by close observation for psychotic symptoms.


Subject(s)
Analgesics, Opioid/adverse effects , Antipsychotic Agents/adverse effects , Dystonia/chemically induced , Morphine/adverse effects , Psychoses, Substance-Induced/etiology , Risperidone/adverse effects , Administration, Oral , Analgesics, Opioid/administration & dosage , Delayed-Action Preparations , Diagnosis, Dual (Psychiatry) , Drug Substitution , Female , Humans , Long QT Syndrome/chemically induced , Methadone/administration & dosage , Middle Aged , Opiate Substitution Treatment , Opioid-Related Disorders/rehabilitation , Schizophrenia/drug therapy , Syndrome
15.
Acta Neurol Scand ; 134(2): 101-7, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26427765

ABSTRACT

BACKGROUND: A complex relationship exists between postural control and cognition in the elderly. Namely, neural mechanisms that are required for the regulation of posture have been variably associated with cognitive dysfunctions. Parkinson's disease (PD) is the second most common neurodegenerative disease among the elderly, and it has been associated with both cognitive and postural abnormalities such as Pisa syndrome (PS). Although its onset has been considered to be multifactorial, the pathophysiological mechanisms underpinning PS are still not fully explained. Until now, no study investigated the possible contribution of cognitive dysfunction to occurrence of PS in PD. PATIENTS AND METHODS: Twenty PD patients with PS and 20 PD patients without PS were enrolled. All patients with PD underwent neuropsychological battery to assess behavioural disturbances, memory, attention, frontal/executive and visuospatial functions. RESULTS: The two groups did not differ on demographic features, age at PD onset and disease duration, whereas they significantly differed on UPDRS-Part III, and levodopa-equivalent daily dose (LEDD). MANCOVA with above-mentioned clinical variable as covariates revealed significant differences on tasks tapping verbal long-term memory, and attentional and visuoperceptual abilities between groups. The binary logistic regression revealed that higher LEDD and lower performance on visuospatial task (Benton Judgment of Lines Orientation test) significantly predicted occurrence of PS. CONCLUSION: Our results revealed a significant association of PS with altered attention and visuoperceptual functions in PD, suggesting that the occurrence of PS may be associated with alteration of both frontal-striatal systems and posterior cortical areas.


Subject(s)
Cognition , Parkinson Disease/diagnosis , Posture , Aged , Attention , Case-Control Studies , Executive Function , Female , Humans , Male , Memory , Middle Aged
16.
Australas Psychiatry ; 24(6): 545-547, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27590078

ABSTRACT

OBJECTIVE: The aim of this paper is to present a case of paliperidone-induced Pisa syndrome and provide treatment experience. METHOD: The case report is combined with a review of the literature. RESULTS: A 37-year-old man had been diagnosed with paranoid-type schizophrenia for about 10 years. He received three-month treatment of paliperidone extended release (ER) at 6 mg per day, but showed a progressively Pisa-like physical position. We initially added an anticholinergic drug, but saw no improvement. The paliperidone ER was replaced by olanzapine at 10 mg per day, and the Pisa-like symptom improved after 1 month of the drug replacement. CONCLUSIONS: We propose olanzapine as a possible replacement choice for patients with paliperidone-related Pisa syndrome.


Subject(s)
Antipsychotic Agents/adverse effects , Benzodiazepines/administration & dosage , Paliperidone Palmitate/adverse effects , Schizophrenia, Paranoid/drug therapy , Adult , Dyskinesia, Drug-Induced/etiology , Dystonia/chemically induced , Humans , Male , Olanzapine , Psychiatric Status Rating Scales , Syndrome
17.
Geriatrics (Basel) ; 9(4)2024 Jul 30.
Article in English | MEDLINE | ID: mdl-39195130

ABSTRACT

BACKGROUND: Pisa syndrome, also known as pleurothotonus, is a neurological condition characterized by more than ten degrees of constant lateral curvature of the spine when upright. In this way, the present manuscript aims to systematically review Pisa syndrome secondary to drugs. METHODS: Two reviewers identified and assessed relevant reports in six databases without language restriction between January 1990 and June 2024. RESULTS: The prevalence of Pisa syndrome varied from 0.037 to 9.3%. We found 109 articles containing 191 cases of drug-induced Pisa syndrome reported in the literature. The mean and median ages were 59.70 (SD = 19.02) and 67 (range = 12-98 years). The most prevalent sex was female, 56.91% (107/188). The most frequent medications associated with Pisa syndrome were acetylcholinesterase inhibitors in 87 individuals. Of 112 individuals in which the onset time from the medication to the movement disorder occurrence was reported, 59 took place within a month. In this way, a return to baseline was observed in 45.50% of the cases, and partial recovery was observed in 14.28%. CONCLUSION: We proposed new diagnostic criteria for Pisa syndrome based on previous findings in the literature. Moreover, multiple mechanisms are probably involved in balance control and the development of lateral trunk flexions.

18.
Gait Posture ; 112: 81-87, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38749293

ABSTRACT

BACKGROUND: Photo-based measurement methods are used to assess axial postural abnormalities (PA) in Parkinson's disease (PD). However, they capture only moments in time. We developed the 2-minute standing endurance test (2 M-SET), which specifically captures temporal changes in posture, as a novel dynamic method for measuring axial PA in patients with PD. RESEARCH QUESTION: This study aimed to verify the effectiveness and validity of the 2 M-SET for capturing temporal changes in axial PA in patients with PD. METHODS: Twenty-eight patients with PD participated. The participants attempted to maintain an upright posture for 2 minutes during three tasks: standing, stepping in place, and walking. The rate of change in postural angle was recorded at 10-second intervals. Based on the results, the 2 M-SET was developed. Therapists evaluated the 2 M-SET using the NeuroPostureApp© to measure anterior trunk flexion (ATF) angles and lateral trunk flexion (LTF) angles at 0, 10, 30, 60, and 120 seconds. To assess reliability, the congruence between the measurements obtained by the therapists and those obtained using a three-dimensional motion-analysis system was examined. For validity, we assessed whether the ATF and LTF angles measured by the therapists could accurately capture postural changes at regular intervals over time. RESULTS: The average postural changes over 2 minutes for the standing, stepping in place, and gait tasks were 59.2±83.5%, 37.6±30.7%, and 45.4±50.6%, respectively. The intraclass correlation coefficients showed high reliability, with values of 0.985 and 0.970 for the ATF and LTF angles, respectively. SIGNIFICANCE: The results of our proposed 2 M-SET method, which uses temporal photo-based measurements to assess the patient's ability to maintain an upright standing position for 2 minutes, demonstrate the potential to capture temporal changes in axial PA. DATA AVAILABILITY STATEMENT: The data supporting the findings of this study are available upon reasonable request and approval from the local ethics committee.


Subject(s)
Parkinson Disease , Postural Balance , Standing Position , Humans , Parkinson Disease/physiopathology , Male , Female , Aged , Postural Balance/physiology , Middle Aged , Reproducibility of Results , Biomechanical Phenomena , Posture/physiology
19.
Ann Pharmacother ; 47(9): 1223-8, 2013 Sep.
Article in English | MEDLINE | ID: mdl-24259741

ABSTRACT

OBJECTIVE: To report a case of risperidone-induced Pisa syndrome in a patient with multiple sclerosis (MS) that resolved with lurasidone, recurred with chlorpromazine, and was complicated by possible drug-drug interactions. CASE SUMMARY: A 31-year-old white male with MS developed Pisa syndrome after years of treatment with risperidone at varying doses for behavioral symptoms associated with pervasive developmental disorder. The patient experienced improvement in symptoms after treatment was switched to lurasidone; however, due to psychiatric decompensation, a switch to chlorpromazine was made and Pisa syndrome recurred. To maintain control of the patient's behavioral symptoms, chlorpromazine was not discontinued. DISCUSSION: Pisa syndrome is a rare adverse drug reaction induced most often by neuroleptic medications. The reaction is characterized by dystonia affecting cervical and lumbar musculature, resulting in flexion of the head and body to one side with axial rotation of the trunk. The etiology is believed to involve a dopaminergic-cholinergic imbalance. Most practitioners are not familiar with this syndrome, and it has not been reported previously in a patient with MS. Definitive diagnostic criteria and treatment have not been established. We identified 15 case reports involving risperidone, paliperidone, chlorpromazine, clomipramine, or valproic acid. The time to development of Pisa syndrome, patient demographics, dosing and titration of causative medications, approach to treatment, and resolution of Pisa syndrome varied widely in these reports. Dystonia in MS often presents differently than Pisa syndrome. The Naranjo probability scale indicated a probable relationship between either risperidone or chlorpromazine in each instance of Pisa syndrome in our patient. CONCLUSIONS: Pisa syndrome is a rare adverse drug reaction associated with neuroleptic medications. Our report highlights the importance of identifying this uncommon type of dystonia in order to consider modification of the medication regimen when appropriate.


Subject(s)
Antipsychotic Agents/adverse effects , Chlorpromazine/adverse effects , Gait Ataxia/chemically induced , Risperidone/adverse effects , Adult , Child Development Disorders, Pervasive/drug therapy , Humans , Isoindoles/therapeutic use , Lurasidone Hydrochloride , Male , Multiple Sclerosis/drug therapy , Recurrence , Syndrome , Thiazoles/therapeutic use
20.
Toxins (Basel) ; 15(9)2023 09 11.
Article in English | MEDLINE | ID: mdl-37755992

ABSTRACT

Lateral trunk flexion (LTF) and its severe form, called Pisa syndrome (PS), are highly invalidating axial postural abnormalities associated with Parkinson's disease (PD). Management strategies for LTF lack strong scientific evidence. We present a real-life, longitudinal study evaluating long-term efficacy of botulinum toxin (BoNT) injections in axial muscles to reduce LTF and PS in PD. A total of 13 PD patients with LTF > 5° received ultrasound- and electromyography-guided BoNT injections every 4 months. Seven untreated matched PD patients with LTF served as controls and their changes in posture after 18 months were compared with those of seven patients continuing BoNT over 12 months. 53.8% of patients continued the BoNT injections for at least 12 months. Various individual LTF responses were observed. Overall, BoNT-treated patients obtained a not statistically significant improvement of LTF of 17 ± 41% (p = 0.237). In comparison, the seven untreated PD patients suffered a deterioration in LTF over 12 months by 36 ± 45% (p = 0.116), showing a significantly different trajectory of posture change (p = 0.026). In conclusion, repeated BoNT injections in axial muscles showed varying effects in managing PD-associated LTF, suggesting that: (a) a relevant number of patients with LTF can benefit from BoNT; (b) long-term treatment could prevent LTF worsening; (c) an instrumented, personalized approach is important; and (d) there is a need for prospective, long-term studies.


Subject(s)
Botulinum Toxins , Parkinson Disease , Humans , Parkinson Disease/drug therapy , Longitudinal Studies , Botulinum Toxins/adverse effects , Electromyography , Muscles , Syndrome
SELECTION OF CITATIONS
SEARCH DETAIL